These Two New AstraZeneca Diabetes Medications With Saxagliptin Are Part Of The Incretin Mimetic Class Of Drugs
SUMMARY: To start, for some background, one might want to read this article, “Possible Link Between Heart Failure And Onglyza Diabetes Type 2 Drug Is Being Investigated By FDA, As Announced In February 2014”, which we posted about a year ago.
At an April 14, 2015 meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee, results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial for for AstraZeneca’s relatively new diabetes drugs Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin HCI extended-release) will be discussed.
Besides saxagliptin (Onglyza, Kombiglyze XR), other diabetes drugs in the incretin mimetic class besides include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).
We will watch for further developments surrounding the safety profile of Onglyza and Kombiglyze XR as well as these other incretin mimetic diabetes drugs.[Read this article in full at original source]
Strictly Confidential, No Obligation